ASH 2014 | Phase II trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia
Christoph Röllig
• 6 Dec 2014
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Christoph Röllig (Universitätsklinikum Dresden, Dresden, Germany) discusses the phase II Study Alliance Leukemia (SAL)-Soraml trial, which evaluated sorafenib versus placebo in addition to standard therapy in younger patients (18–60 years old) with newly diagnosed acute myeloid leukaemia. improves event-free survival and relapse-free survival rate in younger patients with newly-diagnosed acute myeloid leukaemia.
